Publication

Incretin combination therapy for the treatment of non-alcoholic steatohepatitis

Diabetes, Obesity and Metabolism 22(8):1328-1338, 2020

Kannt A, Nygaard Madsen A, Kammermeier C, Elvert R, Klöckener T, Bossart M, Haack T, Evers A, Lorenz K, Hennerici W, Rocher C, Böcskei Z, Guillemot JC, Mikol V, Pattou F, Staels B, Wagner M

View publication

Subjects
Therapeutic AreaTargetMouseCompoundMethod/EndpointAMLN DIO-NASH (AMLN DIO-MASH) mouseSpeciesBody compositionBody weightBlood biochemistryNon-alcoholic steatohepatitis/Metabolic dysfunction-associated steatohepatitis (NASH/MASH)GIP receptorGLP-1 receptorGlucagon receptorGIP receptor agonistImage analysisGLP-1 receptor agonistGlucagon receptor agonistLiver biopsyLiver morphometryReal-time food intake/activity analysisLiraglutideRNA sequencing

Share this page

Resource Library

Related resources
Poster
Obeticholic acid improves histological, biochemical and gene expression profiles in Gubra AMLN mice with diet-induced and biopsy-confirmed NASH
Publication
Animal models of type 2 diabetes, obesity and nonalcoholic steatohepatitis – clinical translatability and applicability in preclinical drug development
Poster
Prophylactic and therapeutic hepatoprotective effects of lanifibranor in the CDAA-HFD mouse model of advanced NASH with progressive fibrosis
Poster
Preclinical efficacy and clinical translatability of elafibranor in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH 

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 ­2650

Back To Top